---
title: "EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292896946.md"
description: "EyePoint, Inc., a company based in Watertown, Mass., disclosed on July 16, 2026, that it has issued non-statutory stock options to new employees as part of their inducement awards. These options were granted outside of the company's 2023 Long-Term Incentive Plan. EyePoint, Inc. is listed on the Nasdaq under the symbol EYPT and focuses on developing and marketing therapies to aid patients with serious retinal ailments. This move aligns with NASDAQ Listing Rule 5635(c)(4) regulations."
datetime: "2026-07-16T11:03:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292896946.md)
  - [en](https://longbridge.com/en/news/292896946.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292896946.md)
---

# EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint, Inc., a company based in Watertown, Mass., disclosed on July 16, 2026, that it has issued non-statutory stock options to new employees as part of their inducement awards. These options were granted outside of the company's 2023 Long-Term Incentive Plan. EyePoint, Inc. is listed on the Nasdaq under the symbol EYPT and focuses on developing and marketing therapies to aid patients with serious retinal ailments. This move aligns with NASDAQ Listing Rule 5635(c)(4) regulations.

### Related Stocks

- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)

## Related News & Research

- [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News](https://longbridge.com/en/news/295973644.md)
- [EyePoint stock craters 71% after drug trial failure. It may be an overreaction.](https://longbridge.com/en/news/296132806.md)
- [EyePoint says Phase 3 LUGANO trial of DURAVYU in wet AMD misses primary endpoint](https://longbridge.com/en/news/296094908.md)
- [EyePoint rebounds after selloff despite multiple downgrades](https://longbridge.com/en/news/296243335.md)
- [EYPT: DURAVYU reduced treatment burden by 42% and maintained strong safety in wet AMD](https://longbridge.com/en/news/296109785.md)